Literature DB >> 5049924

Combination phase 1-II study of imidazole carboxamide (NCS45388).

D E Wagner, G Ramirez, A J Weiss, G Hill.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 5049924     DOI： 10.1159/000224680

Source DB:  PubMed          Journal:  Oncology        ISSN： 0030-2414            Impact factor:   2.935


× No keyword cloud information.
  10 in total

1.  Evaluation of fludarabine phosphate in malignant melanoma. A Southwest Oncology Group study.

Authors:  J A Kish; K Kopecky; M K Samson; D D Von Hoff; W S Fletcher; R A Kempf; F M Muggia
Journal:  Invest New Drugs       Date:  1991-02       Impact factor: 3.850

Review 2.  Preclinical Development of Seriniquinones as Selective Dermcidin Modulators for the Treatment of Melanoma.

Authors:  Amanda S Hirata; James J La Clair; Paula C Jimenez; Leticia Veras Costa-Lotufo; William Fenical
Journal:  Mar Drugs       Date:  2022-04-28       Impact factor: 6.085

3.  Clinical pharmacokinetics of high-dose DTIC.

Authors:  J M Buesa; E Urréchaga
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Combination chemotherapy with ifosfamide and cis-dichlorodiammineplatinum (II) in advanced malignant melanoma.

Authors:  R Becher; S Seeber; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

Review 5.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma.

Authors:  C I Falkson
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

7.  Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma.

Authors:  P J Frosch; B M Czarnetzki; E Macher; E Grundmann; I Gottschalk
Journal:  J Cancer Res Clin Oncol       Date:  1979       Impact factor: 4.553

8.  Chemotherapy of malignant melanoma with dimethyl traizeno imidazole carboxamide (DITC) and nitrosourea derivatives (BCNU, CCNU).

Authors:  G J Hill; R Ruess; R Berris; G W Philpott; P Parkin
Journal:  Ann Surg       Date:  1974-08       Impact factor: 12.969

Review 9.  WITHDRAWN: Systemic treatments for metastatic cutaneous melanoma.

Authors:  Tom Crosby; Reg Fish; Bernadette Coles; Malcolm Mason
Journal:  Cochrane Database Syst Rev       Date:  2018-02-07

10.  Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.

Authors:  E S Newlands; C J Oon; J T Roberts; P Elliott; R F Mould; C Topham; F J Madden; K A Newton; G Westbury
Journal:  Br J Cancer       Date:  1976-08       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.